Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE KIDNEY I: AntiBKV in Healthy Volunteers
NCT05358106Phase 1Completed
- Sponsor
- Memo Therapeutics AG
- Start
- May 2022
- Primary completion
- Dec 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in BK virus infection and BK virus nephropathy (BKVN) comparing AntiBKV (Potravitug) with Placebo (2 arms). Primary endpoints: Number of participants with treatment-related adverse events, Change in blood haematology values and 5 more. Started May 2022; status: completed.
02
Drugs
potravitug
03
Conditions
BK virus infectionBK virus nephropathy (BKVN)
Beyond the preview
Go deeper on NCT05358106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05358106.